> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Viatris Adds Non-Opioid Pain Business With Approximately $1.69 Billion Pacira Purchase
- URL: https://www.bullished.co/viatris-adds-non-opioid-pain-business-with-approximately-1-69-billion-pacira-purchase-95a94673/
- Published: 2026-11-17T14:51:04.000Z
- Updated: 2026-11-17T14:51:04.000Z
- Description: Viatris expects Pacira to contribute $90 million to $100 million in revenue for the remainder of 2026.
- Author: Matteo Parrino
- Tags: SEC Filings, VTRS, Industry: Healthcare

[Viatris](https://www.bullished.co/tag/vtrs/), which supplies generic, brand-name and innovative medicines worldwide, completed its approximately [$1.69 billion purchase](https://www.sec.gov/Archives/edgar/data/0001792044/000114036126044356/ef20085674%5F8k.htm?ref=bullished.co) of Pacira BioSciences on Tuesday. The deal brings the non-opioid pain-management company into Viatris as it expands its U.S. innovative medicines business, according to its SEC filing and accompanying company release.

## Pain Medicines Join A Global Portfolio

Viatris expects Pacira to generate [$90 million to $100 million](https://www.sec.gov/Archives/edgar/data/0001792044/000114036126044356/ef20085674%5Fex99-1.htm?ref=bullished.co) in revenue for the rest of 2026, covering November 17 through December 31\. That forecast gives investors a first measure of the business's expected contribution now that the acquisition is complete.

Scott A. Smith, Viatris' CEO, said the deal advances its strategy to "strengthen our [U.S. innovative medicines](https://www.sec.gov/Archives/edgar/data/0001792044/000114036126044356/ef20085674%5Fex99-1.htm?ref=bullished.co) business." Smith said he aims to establish a leading position in non-opioid pain management and accelerate sustained growth in revenue and earnings.

Viatris' existing portfolio includes complex generics and established branded drugs alongside its expanding innovative-medicines business. The company reported $14.30 billion in total revenue in 2025 and operates across Developed Markets, Emerging Markets, JANZ and Greater China.

Its medicines reach patients through pharmacies, retailers, wholesalers, governments, institutions and physicians. Its global footprint spans more than 165 countries and territories, with more than 30,000 employees and 27 sites for manufacturing, packaging and distribution.

## Cash Terms For Pacira Holders

Pacira shareholders receive [$36.50 per share](https://www.sec.gov/Archives/edgar/data/0001792044/000114036126044356/ef20085674%5F8k.htm?ref=bullished.co) in cash under the offer. The approximately $1.69 billion total excludes transaction fees and expenses, and Viatris will pay for the purchase using available cash and short-term borrowing.

Viatris signed the merger agreement on October 8, 2026, and launched the offer to buy shareholders' stock on October 30\. The offer and the right to withdraw tendered shares expired one minute after 11:59 p.m. Eastern Time on Monday.

Shareholders [tendered 32,929,780 shares](https://www.prnewswire.com/news-releases/viatris-completes-acquisition-of-pacira-biosciences-302942214.html?ref=bullished.co) without withdrawing them, representing approximately 66.46% of Pacira's outstanding stock. That participation allowed the merger to proceed without a Pacira shareholder vote.

Pacira is now wholly owned by Viatris. Shares that were not tendered generally became rights to receive the same cash price; holders who properly exercised appraisal rights are subject to the separate appraisal process.

Pacira shares will be delisted from the Nasdaq Global Select Market as a result of the completed acquisition.

Learn

- [Item 2.01: completion of an acquisition or disposition →](https://www.bullished.co/learn/8-k-items-explained/#item-201-completion-of-an-acquisition-or-disposition)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Viatris Inc (VTRS)](https://www.sec.gov/Archives/edgar/data/0001792044/000114036126044356/ef20085674%5F8k.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit ef20085674\_ex99-1.htm — Viatris Inc 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001792044/000114036126044356/ef20085674%5Fex99-1.htm?ref=bullished.co) — SEC EDGAR
- [Viatris Completes Acquisition of Pacira BioSciences](https://www.prnewswire.com/news-releases/viatris-completes-acquisition-of-pacira-biosciences-302942214.html?ref=bullished.co) — prnewswire.com

### More on Viatris

- [Viatris Raises 2026 Profit Targets Despite A $325 Million Quarterly Loss](https://www.bullished.co/viatris-raises-2026-profit-targets-despite-a-325-million-quarterly-loss-bd327c98/)
- [Viatris CEO Won't Guide 2027 But Calls Analyst's EBITDA Math 'In The Ballpark'](https://www.bullished.co/viatris-ceo-wont-guide-2027-but-calls-analysts-ebitda-math-in-the-ballpark-64d2777d/)
- [Viatris Agrees To Buy Pacira For $36.50 A Share, A $1.65 Billion Bet On Non-Opioid Pain Drugs](https://www.bullished.co/viatris-agrees-to-buy-pacira-for-36-50-a-share-a-1-65-billion-bet-on-non-opioid-pain-drugs-d939be3e/)

[All Viatris (VTRS) coverage →](https://www.bullished.co/tag/vtrs/)